Loading stock data…
LB Pharmaceuticals Inc (LBRX)
$32.64+0.72 (+2.26%)
Market ClosedLast close Jun 29
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LB Pharmaceuticals Inc in the Healthcare sector is trading at $32.64 with a market capitalization of $802M. Wall Street consensus targets $45.00 (6 analysts), implying a +37.9% move over the next 12 months. The stock is currently near its 52-week high of $33.47, remaining 43.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +37.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$22.10M↓ | -$13.87M↓ | -$5.25M↓ | -$4.86M↑ | -$6.43M |
| Net Income | -$19.05M↓ | -$11.47M↓ | -$3.56M↑ | -$4.87M↑ | -$5.31M |
Peer Comparison
JNJUNHPFE
Fundamentals
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$801.51M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-10.29%
Volume
Today's trading volume
362,936
Recent News
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
LB Pharmaceuticals Inc (LBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham
LB Pharmaceuticals (NASDAQ:LBRX) is seeking to build a “fully integrated company focused on CNS-related diseases,” Chief Executive Officer Heather Turner said during a presentation at a Needham conference hosted by biotech analyst Ami Fadia. Turner said the company’s lead program, LB-102, is a late
LB Pharmaceuticals Inc.: Q4 Earnings Snapshot
NEW YORK (AP) — LB Pharmaceuticals Inc. LBRX) on Thursday reported a loss of $11.5 million in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 45 cents.